CN Patent

CN116601151A — Kras g12c抑制剂的晶型

Assigned to Mirati Therapeutics Inc · Expires 2023-08-15 · 3y expired

What this patent protects

本发明涉及KRas G12C抑制剂及其盐的晶型。具体地，本发明涉及KRas G12C抑制剂2‑[(2S)‑4‑[7‑(8‑氯‑1‑萘基)‑2‑[[(2S)‑1‑甲基吡咯烷‑2‑基]甲氧基]‑6,8‑二氢‑5H‑吡啶并[3,4‑d]嘧啶‑4‑基]‑1‑(2‑氟丙‑2‑烯酰基)哌嗪‑2‑基]乙腈的晶型、包含所述晶型的药物组合物、用于制备所述晶型的过程及其使用方法。

USPTO Abstract

本发明涉及KRas G12C抑制剂及其盐的晶型。具体地，本发明涉及KRas G12C抑制剂2‑[(2S)‑4‑[7‑(8‑氯‑1‑萘基)‑2‑[[(2S)‑1‑甲基吡咯烷‑2‑基]甲氧基]‑6,8‑二氢‑5H‑吡啶并[3,4‑d]嘧啶‑4‑基]‑1‑(2‑氟丙‑2‑烯酰基)哌嗪‑2‑基]乙腈的晶型、包含所述晶型的药物组合物、用于制备所述晶型的过程及其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116601151A
Jurisdiction
CN
Classification
—
Expires
2023-08-15
Drug substance claim
No
Drug product claim
No
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.